Gilead Sciences Inc.’s earnings fell less than expected in the most recent quarter as declining drug sales were partially offset by cost cuts, but executives warned the worst is yet to come for its hepatitis C treatments, which saw a 33% sales decline during the period.
from WSJ.com: US Business http://ift.tt/2zIaH0k
via IFTTT
No comments:
Post a Comment